ArticleDiscover oncology2025
Tumor size in the management of preoperative radiotherapy for locally advanced rectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo identify tumor size could be taken as a decision-making factor in the management of preoperative radiotherapy (RT) for patients with locally advanced rectal cancer (LARC).
methodsIn this study, patients diagnosed with rectal adenocarcinoma and staged at II/III from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2014 were included. Kaplan-Meier curve was conducted to investigate the overall survival (OS) between subgroups with different tumor sizes and the relationship between the tumor size and the efficacy of preoperative RT.
resultsThere were 1402 patients eligible for this study, of whom 1105 (78.8%) received preoperative radiotherapy (RT + S group) and 297 (21.2%) underwent surgery alone (S group). The median OS was comparable between groups of RT + S and S before and after propensity score matching (both P > 0.05), but tumor size was a robust independent risk factor of OS (P < 0.05). 5 cm was then identified to the optimal cut-off value of tumor size using the minimum P value. Further analysis showed that preoperative RT could only benefit those with tumor size > 5 cm (P < 0.05); while on the contrary, it would hamper the OS of those with tumor size ≤ 5 cm and no OS risk factors (P > 0.05).
conclusionData from this retrospective analysis of patients with LARC seems to indicate that tumor size might play a role in the decision-making process for (tumors > 5 cm) or against (tumors ≤ 5 cm) preoperative radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.